|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Bear HD et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24(13):2019-27. Abstract
Berry DA et al. Estrogen-receptor status and outcomes of modern chemotherapy for
patients with node-positive breast cancer. JAMA 2006;295(14):1658-67. Abstract
Fisher B et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen
receptor-positive breast cancer. J Natl Cancer Inst 1997;89(22):1673-82. Abstract
Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract
Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with
docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
J Clin Oncol 2006;24:5381-7. Abstract
Jones SE et al. Three year results of a prospective randomized trial of adjuvant chemotherapy for patients (pts) with stage I-III operable, invasive breast cancer comparing 4 courses of doxorubicin/cyclophosphamide (AC) to 4 courses of docetaxel/cyclophosphamide (TC). Proc ASCO 2003;Abstract 59.
Paik S et al. Gene expression and benefit of chemotherapy in women with node negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34.
Abstract
Singletary SE, Connolly JL. Breast cancer staging: Working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 2006;56(1):37-47. Abstract
Wolmark N et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;(30):96-102. Abstract
 |
 |
